News
Freshfields lands major US mandate advising Merck on $10bn Verona Pharma acquisition opposite Latham
Freshfields is advising Merck on its $10bn acquisition of respiratory-focused pharmaceutical company Verona Pharma, in a ...
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co.’s $10 billion ...
Fintel reports that on July 10, 2025, Wells Fargo downgraded their outlook for Verona Pharma plc - Depositary Receipt () ...
Merck says it will acquire London-based Verona Pharma for about US$10bil, gaining a promising respiratory treatment as it ...
19h
Dealbreaker on MSNMerck Breathes Life Into Its Respiratory Prospects With $10B Deal to Buy Verona PharmaVerona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...
This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...
A key patent for Merck’s blockbuster drug Keytruda will expire in 2028. The cancer therapy brought the company $29.5 billion last year. Keytruda may also face “ price setting ” from the Inflation ...
The effort appears to be paying off – last year Johnson & Johnson turned to Freshfields over its usual choice Cravath for its $13bn acquisition of medical device maker Shockwave Medical, with the team ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results